FDA pub­lish­es On­copep­tides’ with­draw­al ap­peal for Swedish biotech’s can­cer drug Pepax­to

On­copep­tides’ ap­peal to the FDA’s with­draw­al pro­pos­al for the blood can­cer drug Pepax­to has been made pub­lic, shed­ding new light on the see­saw­ing that’s been go­ing on at the Swedish biotech.

Pepax­to has been on a rocky jour­ney since its ac­cel­er­at­ed ap­proval in ear­ly 2021 for use in com­bi­na­tion with dex­am­etha­sone as a fifth-line treat­ment for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma. The FDA alert­ed pa­tients in the sum­mer of 2021 that the con­fir­ma­to­ry tri­al was halt­ed af­ter con­cerns of in­creased risk of death in pa­tients tak­ing a com­bi­na­tion of Pepax­to (mel­pha­lan flufe­namide) and dex­am­etha­sone. FDA’s re­view­ers con­clud­ed that a con­fir­ma­to­ry tri­al did not show safe and ef­fi­ca­cious treat­ment ben­e­fit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER